Hepatitis G virus and molecular cloning thereof

• US 5,849,532 A
• Filed: 06/06/1995
• Issued: 12/15/1998
• Est. Priority Date: 05/20/1994
• Status: Expired due to Fees

• Current Assignee: Genelabs Technologies, Inc. (GlaxoSmithKline PLC)
• Original Assignee: Genelabs Technologies, Inc. (GlaxoSmithKline PLC)
• Inventors: Linnen, Jeffrey M., Wages, John, Fry, Kirk E., Kim, Jungsuh P., Young, LaVonne Marie
• Primary Examiner(s): Woodward, Michael P.
• Assistant Examiner(s): BRUMBACK, BRENDA G
• Application Number:
  US08/464,134
• Time in Patent Office: 1,288 Days
• Field of Search: 435/320.1, 435/252.3, 435/69.1, 435/69.3
• US Class Current: 435/69.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/36022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: Y10S 530/826 Viruses

Abstract

Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

Claims

1. A vector comprising a Non-A Non-B Non-C Non-D Non-E Hepatitis Virus (HGV) polynucleotide composed of a contiguous series of nucleotides contained in SEQ ID NO:

14 operably linked to a control sequence, where said polynucleotide encodes a product at least 10 amino acids in length,

wherein HGV is characterized by;

(i) production of elevated serum alanine aminotransferase levels in an infected primate, (ii) its serological distinction from hepatitis virus (HAV) hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus, and hepatitis E virus (HEV), (iii) membership in the virus family Flaviviridae and (iv) a viral genome comprising a polynucleotide region that is selectively hybridizable with SEQ ID NO;

19.

2. A cell transformed with the vector of claim 1.

3. A method of producing a Non-A Non-B Non-C Non-D Non-E Hepatitis Virus (HGV) polypeptide, comprising culturing the cell of claim 2 under conditions effective to promote expression of the product.

4. The method of claim 3, where said polynucleotide encodes a polypeptide whose sequence is contained in SEQ ID NO:

15.

5. The method of claim 3, where the vector is a lambda gt11 phage vector and the cell is Escherichia coli.

6. A host cell transformed with the vector of claim 1.

7. The method of claim 3, where the vector is a baculovirus transfer vector and the cell is a Spodoptera frugiperda cell.